
Opinion|Videos|December 22, 2023
Safety of Available JAK Inhibitors for Treatment of MF
Author(s)Aaron T. Gerds, MD, MS
Aaron Gerds, MD, MS, reviews key safety concerns seen with JAK inhibitors for myelofibrosis treatment.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































